Kohlberg Kravis Roberts & Co. L.P.

NEW YORK, NY · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 13, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$5.04B2026 Q3
Positions103
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.95.7%

Kohlberg Kravis Roberts & Co. L.P. reported 103 positions worth $5.04B as of September 30, 2026 (13F filed November 13, 2026). Largest holding: BTSG (30.2%).

10 / 103 positions shown
#SymbolCompanyValue ↓% Port.Shares1YYTDSince reported
▸ 1 BTSGBrightSpring Health Services$1.52B30.23%26,829,880——+25.8%
▸ 2 HSICHenry Schein$1.31B26.09%15,652,032——+1.2%
▸ 3 BBIOBridgeBio Pharma$543.6M10.79%8,260,971——+17.6%
▸ 4 NIQNIQ Global Intelligence$510.7M10.14%30,022,789——+10.4%
▸ 5 CRGYCrescent Energy$369.4M7.33%28,655,357——-10.3%
▸ 6 BVBrightView$219.1M4.35%21,533,123——-6.3%
▸ 7 GMRSGMR Solutions$142.4M2.83%14,785,611——+19.8%
▸ 8 NCLH 0.75 09-15-30NCL$96.5M1.92%$114.5M principal———
▸ 9 KREFKKR Real Estate$62.1M1.23%10,000,001——-12.7%
▸ 10 NCLH 0.875 04-15-30NCL$39.7M0.79%$43.5M principal———

Pro Feature

The remaining 93 positions with Pro.

Upgrade to Pro

Read the 2026-Q2 quarterly report · 13F Filing Calendar

🔔 Tell me when this fund files a new 13F

No account needed: in your inbox the morning it is published.

Frequently Asked Questions

What stocks does Kohlberg Kravis Roberts & Co. L.P. hold as of Q3 2026?

Kohlberg Kravis Roberts & Co. L.P. reported 103 positions worth $5.04B in its Q3 2026 13F filing. Largest positions: BTSG (30.2%), HSIC (26.1%), BBIO (10.8%), NIQ (10.1%) and CRGY (7.3%).

What did Kohlberg Kravis Roberts & Co. L.P. buy in Q3 2026?

No previous quarter is available yet; the comparison appears with the next filing.

What did Kohlberg Kravis Roberts & Co. L.P. sell in Q3 2026?

No previous quarter is available yet.

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.